

Supplemental Tables for:  
 Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients  
 Shanly C. Seferina et al.

**Table S1. Overview of patient and tumor characteristics for indication of chemotherapy and trastuzumab in HER2 positive early breast cancer according to:**

| Dutch guideline 2005 (11)   | Dutch guideline 2012 (1)   |
|---|--|
| Node positive<br>< 60 years<br>≥60 - <70 years<br>≥ 4 positive nodes<br>ER/PR negative<br><br>Node negative<br>≤ 35 years except if tumor size ≤10mm + grade 1<br>35-<60 years irrespective ER/PR status<br>tumor size >10mm - <20mm + grade 3<br>tumor size ≥20mm - <30mm + grade 2 or 3<br>tumor size ≥30mm<br><br>≥60 -<70 years + ER/PR negative<br>tumor size >10mm - <20mm + grade 3<br>tumor size ≥20mm - <30mm + grade 2 or 3<br>tumor size ≥30mm | Node positive<br><70 years<br>>70 if fit and in good clinical condition<br><br>Node negative<br><br>HER2+positive tumors<br>>0.5cm |

**Table S2. Baseline characteristics of patient treated with trastuzumab in Randomized Controlled Trials vs. Real Life (irrespective of indication according to guideline)**

| Characteristics             | This study | HERA(2)    | NSABP-B31(14) | NCCTG<br>N9831(14) | BCIRG-006(4) | FinHER(5)   | PACS04(6) |
|-----------------------------|------------|------------|---------------|--------------------|--------------|-------------|-----------|
| Included patients - no.     | 230        | 1694       | 864           | 808                | 1074         | 232         | 260       |
| Age at diagnosis, years - % |            |            |               |                    |              |             |           |
| < 35 yr                     | 3          | 8          | -             | -                  | -            | -           | -         |
| ≤ 39 yr                     | -          | -          | 16            | 16                 | -            | -           | -         |
| 35-49 yr                    | 38         | 44         | -             | -                  | -            | -           | -         |
| 40-49 yr                    | -          | -          | 35            | 34                 | -            | -           | -         |
| 50-59 yr                    | 40         | 32         | 32            | 32                 | -            | -           | -         |
| ≥ 60 yr                     | 19         | 16         | 16            | 18                 | -            | -           | -         |
| Median                      | 51         | 49         | -             | -                  | -            | 51          | 48        |
| Pathological tumor size - % |            |            |               |                    |              |             |           |
| <1cm                        | -          | -39        | -37           | -38                | -38          | 7           | -         |
| >1-2cm                      | 44         | 39         | 37            | 38                 | 38           | 33          | 41        |
| ≥ 2 cm                      | 56         | 49         | 62            | 61                 | 62           | 59          | 59        |
| Nodal status - %            |            |            |               |                    |              |             |           |
| Negative                    | 44         | 32         | 0             | 11                 | 28           | 10          | -         |
| 1-3 Positive nodes          | 34         | 29         | 57            | 50                 | 38           | 55          | 60        |
| ≥ 4 Positive nodes          | 21         | 28         | 33            | 39                 | 33           | 34          | 40        |
| Hormone-receptor status - % |            |            |               |                    |              |             |           |
| ER and/or PR positive       | ER/PR+:62  | ER:46PR:36 | ER:52 PR:39   | ER:51PR:39         | ER/PR+:54    | ER:50/PR:39 | ER/PR+:58 |

**Table S2. (Continued)**

| Characteristics                         | This study                                   | HERA(2)     | NSABP-B31(14)                                    | NCCTG N9831(14) | BCIRG-006(4)  | FinHER(5)  | PACS04(6)  |
|---|--|-------------|--|-----------------|---------------|------------|------------|
| Included patients - no.                 | 230  | 1694        | 864  | 808             | 1074          | 232        | 260        |
| Extent of surgery for primary tumor - % | -  | 100         | 100  | 100             | -             | 100        | -          |
| Breast-conserving procedure             | 42   | -           | -  | -               | -             | -          | 62         |
| Mastectomy                              | 58   | -           | -  | -               | 63            | -          | 38         |
| Type of (neo)adjuvant chemotherapy - %  |  |             |  |                 |               |            |            |
| Anthracyclines                          | 37   | 68          | -  | -               | -             | 52         | 52         |
| Taxanes                                 | 2  | -           | -  | -               | -             | -          | -          |
| Anthracycline and Taxanes               | 60   | 26          | 100  | 100             | 100           | 48         | 48         |
| Others                                  | 1  | 6           | -  | -               | -             | -          | -          |
| Adjuvant endocrine therapy given - %    |  |             |  |                 |               |            |            |
| Yes                                     | 58   | 90          | 56   | 48              | 50            | 71/74      | 58         |
| Hazard Ratio Disease-free Survival      | 0.63 (5yrs)*<br>0.56 (5yrs)+<br>0.75 (5yrs)± | 0.85 (4yrs) | 0.52 (4yrs)<br>(joint analysis NCCTG/NSABP B-31) |                 | 0.64 (5.4yrs) | 0.65(5yrs) | 0.86(4yrs) |

\*real life scenario, + Indication for trastuzumab,± No Indication for trastuzumab corrected for age, Charlson Comorbidity Index, pathological tumor size, nodal status and grade

**Table S3. Disease-free and overall survival in real life trastuzumab patients as compared to patients treated with trastuzumab in the HERA trial and NCCTG/NSABP joint analysis**

|                       | Real life trastuzumab<br>n=230 | HERA trial(17, 20, 21)<br>n=1694 | NCCTG/NSABP joint<br>analysis(14)<br>n=2028 |
|-----------------------|--------------------------------|----------------------------------|---|
| Disease-free survival | %                              | %                                | %   |
| 3 year                | 90.0                           | 85.7                             | 88.0  |
| 4 year                | 82.5                           | 78.6                             | 85.7  |
| 5 year                | 80.7                           | 75.9                             | 83.3  |
| Overall survival      |                                |                                  |   |
| 3 year                | 96.1                           | 92.4                             | 95.1  |
| 4 year                | 92.3                           | 89.3                             | 93.0  |
| 5 year                | 90.7                           | 86.9                             | 91.3  |